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Abstract
Background: Single nucleotide polymorphisms
(SNPs) of mitochondrial DNA (mtDNA) are involved
in physiological and pathological conditions. We
developed a rapid, accurate, highly sensitive and
high-throughput approach with low cost to identify
mtDNA SNPs.
Methods: Matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF MS)
was used to detect 18 SNPs of mtDNA by uniplex and
multiplex assays. The sensitivity and specificity of the
MALDI-TOF MS were evaluated. The accuracy of the
approach was validated by the comparison of using
the robust sequencing analysis.
Results: The detection limit achieved with the assays
corresponded to the identification of five-genome
equivalence of mtDNA per reaction after first round
PCR amplification. The testing system enabled the
discrimination of as little as 5% of mtDNA polymor-
phism in the predominating background of mtDNA
not containing the SNP. No false positive and false
negative results were obtained using the uniplex and
multiplex MALDI-TOF MS assays for the analysis of
the 18 SNPs compared with those obtained by
sequencing analysis.
Conclusions: Possible fields which could benefit from
this powerful and sensitive tool include forensic med-
icine, tracing of matrilineage, transplantation immu-
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nology, transfusion medicine, the diagnosis of
mtDNA mutation related disorders, and the research
regarding aging, apoptosis and carcinogenesis based
on physiologic and pathogenic alterations of mtDNA
for the analysis of large-scale samples, multiple SNPs
or rare mtDNA.
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Introduction
Mitochondrial DNA (mtDNA) is a circular cytoplasmic
double stranded DNA of 16.6 kb, including the coding
regions and the hypervariable non-coding D-loop
region (1, 2). The features of mtDNA, such as matri-
lineal inheritance, high copy numbers per cell and
lack of recombination make it a powerful tool in life
science.
Physiologically, mtDNA typing has been applied
routinely in forensic medicine (3). Maternal inheri-
tance of mtDNA enables the tracing of matrilineage
far back in time (4). Single nucleotide polymorphisms
(SNPs) can also be used as markers in transfusion and
transplantation medicine (5).
Pathologically, the properties of mtDNA, such as
reactive oxygen species enhanced aggression, high
sensitivity to damage, deficient repair of damage and
high rate of mutations suggest their potential impor-
tance in mtDNA related disorders, aging, apoptosis
and carcinogenesis (6–8). Somatic mutations in
mtDNA have been identified in various human can-
cers and in a large spectrum of clinically important
disorders (9, 10).
Based on the importance of mtDNA SNPs in life sci-
ence, a rapid, accurate, highly sensitive and high-
throughput approach with low cost to identify
physiologic and pathogenic mtDNA variants is need-
ed for the analysis of large-scale samples, multiple
SNPs or rare mtDNA.
Matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) proved to
be a superior, high-throughput technology for the
robust detection of single nucleotide variations with
low cost on nuclear DNA (nDNA). It could permit the
reliable detection of SNPs (11) from a very rare target,
including fetal point mutations from cell-free fetal
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DNA in maternal plasma and donor derived cell-free
DNA in organ transplant recipients urine, which can-
not be reliably detected by more conventional PCR-
based approaches (12, 13).
In this study, we developed a MALDI-TOF MS-based
method to detect 18 SNPs in mtDNA on mtDNA
hypervariable regions in platelet-apheresis products
by uniplex and multiplex assays. This novel applica-
tion enables the rapid, sensitive and accurate identi-
fication of single or multiple mtDNA SNP variants in
a single reaction on mtDNA hypervariable regions.
Materials and methods
DNA extraction
Platelet-apheresis products containing mtDNA from three
blood donors with informative mtDNA SNPs were provided
by the Institute for Clinical Transfusion Medicine, Staed-
tisches Klinikum Braunschweig gGmbH, Germany. This
study was approved by the Local Ethics Committee ’’Ethik-
kommission beider Basel’’. Written informed consent was
obtained from all three individuals. A total of 18 mtDNA
SNPs on three hypervariable regions (HVR1, HVR2 and
HVR3) within the displacement loop (D-loop) region of the
mtDNA were identified using a traditional sequencing
approach by the Institute (5).
For our study, mtDNA was isolated from 800 mL of plate-
letapheresis products using the MagNA LC Isolation Kit-
Large Volume protocol with the MagNA Pure LC Instrument
(Roche Applied Science, Basel, Switzerland) according to the
manufacturer’s introduction. The DNA preparations were
eluted in 200 mL elution buffer according to this protocol.
Quantification of mtDNA and contamination of
nDNA in the samples
The amounts of nDNA and mtDNA were quantified by
multiplex TaqMan real-time PCR for both glyceraldehype-3-
phosphodehydrogenase (GAPDH) gene and mtDNA
sequence.
The GAPDH and mtDNA primer and probe sequences are
shown as follows: GAPDH (14): forward, 59-CCCCACACACA-
TGCACTTACG-39, reverse, 59-CCTAGTCCCAGGGCTTTGATT-
39, probe, 59-(MGB) GTGAACGTGGATGAAGTTGG (VIC)-39;
mtDNA (15): forward, 59-AATATTAAACACAAACTACCACC-
TACC-39, reverse, 59-TGGTTCTCAGGGTTTGTTATA-39, probe,
59-(MGB) CCTCACCAAAGCCCATA (FAM)-39.
The PCR was performed using the ABI PRISM 7000
Sequence Detection System (Applied Biosystems, ABI, Rot-
kreuz, Switzerland). DNA (5 mL) was used as template for the
PCR analysis. The TaqMan assays were carried out in 25 mL
of total reaction volume using 2 min incubation at 508C, fol-
lowed by an initial denaturation step at 958C for 10 min, and
40 cycles of 15 s at 958C and 1 min at 608C.
To determine the quantification of mtDNA and nDNA pres-
ent in platelet-apheresis product samples, standard dilution
curves using HPLC-purified single-stranded synthetic DNA
oligonucleotides (Microsynth, Balgach, Switzerland) speci-
fying a 79-bp mtDNA amplicon and a 97-GAPDH amplicon
with concentration ranging from 5=107 copies to 5=102 cop-
ies were used. Absolute concentrations of mtDNA and
GAPDH were expressed as genome equivalence (GE/mL) of
platelet-apheresis products.
Detection of mtDNA polymorphisms on
hypervariable regions using MALDI-TOF MS
The PCR and extension primers used to analyze the mtDNA
SNPs were designed using MassArray Assay Design v.3.1
(Sequenom, San Diego, CA, USA) and are listed in Table 1.
The uniplex and multiplex PCR reactions were carried out
in 50 mL PCR cocktail mixes containing 5 mL DNA,
1.626 mM MgCl2, 500 mM dNTP mix, 0.5 U Hot-star Taq Gold
polymerase and primer pairs. The amplification was per-
formed under the following conditions: incubation at 948C
for 15 min, followed by 50 cycles of 948C for 20 s, 568C for
30 s, 728C for 1 min and final extension at 728C for 5 min.
To remove the non-incorporated dNTPs, a shrimp alkaline
phosphatase treatment was performed after the PCR reac-
tion under the following conditions: 378C for 20 min, 858C for
5 min and cooling to 48C.
The iPLEX reaction was performed using the iPLEX cock-
tail mix (Sequenom, San Diego, CA, USA), which contains
buffer, termination mix, enzyme and extension primers,
under the following conditions: 948C for 30 s, followed by 40
cycles of 948C for 5 s, 528C for 5 s, 808C for 5 s, final extension
at 728C for 5 min, then cooling to 48C.
The iPLEX reaction products were desalted using clean
resin to optimize mass spectrometric analysis and dispensed
onto a 384-format SpectroCHIP bioarray using a nanodispen-
ser for MALDI-TOF MS analysis. MassARRAY Workstation
version 3.4 software (Sequenom) was used to process and
analyze iPLEX SpectroCHIP bioarrays. The call rate, exten-
sion rate and peak area for all allele-specific analyses in any
given assay were calculated using the software provided by
the manufacturer. Positive and negative control samples
were run at each step and on each chip.
The specificity of the assay for mtDNA was assessed
through the use of a mitochondria negative cell line, which
was obtained by subculturing that cell line in the presence
of low concentration of ethidium bromide until the cells were
devoid of any mitochondria. The sensitivity of the assay for
detecting mtDNA polymorphisms was assessed through the
five-fold dilution of mtDNA samples containing informative
polymorphisms with concentrations as low as 1 GE/mL, as
well as through mixing known mtDNA SNPs into a predom-
inant background of mtDNA molecules not containing those
polymorphisms.
Results
Co-extraction of mtDNA and nDNA from
platelet-apheresis
mtDNA and nDNA were co-extracted from the plate-
let-apheresis products (Table 2). The GAPDH level,
representing cell-free total nDNA, ranged from 1073
to 4039 GE/mL of platelet-apheresis concentrate in the
platelet-apheresis samples, and the mtDNA level
ranged from 869,667 to 3,492,084 GE/mL of platelet-
apheresis products. The levels of mtDNA were found
to be at least 774- up to 2713-fold higher than nDNA
levels.
Specificity of MALDI-TOF MS for detecting mtDNA
polymorphisms
The specificity of the MALDI-TOF MS for detecting the
18 mtDNA polymorphisms was assessed through the
use of a mitochondria negative cell line (143b rho0).
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Table 1 SNPs in the study cases and sequences of primers.
Sequencing PCR primers
1 263 A-G Forward primer: ACGTTGGATGTTAAGTGCTGTGGCCAGAAG
Reverse primer: ACGTTGGATGATAACAATTGAATGTCTGC
Extension primer: TGAATGTCTGCACAGCC
309 C-CC Reverse primer: ACGTTGGATGCCACTTTCCACACAGACATC
Forward primer: ACGTTGGATGTTAAGTGCTGTGGCCAGAAG
Extension primer: TTTCCACCAAACCCCCCC
315 C-CC Forward primer: ACGTTGGATGGCTGGTGTTAGGGTTCTTTG
Reverse primer: ACGTTGGATGAAATTTCCACCAAACCCCCC
Extension primer: CAAACCCCCCCTCCCCC
2 16189 T-C Forward primer: ACGTTGGATGGGGTTGATTGCTGTACTTGC
Reverse primer: ACGTTGGATGCTTGACCACCTGTAGTACAT
Extension primer: CAATCCACATCAAAACCCCC
152 T-C Forward primer: ACGTTGGATGGTTCGCCTGTAATATTGAACG
Reverse primer: ACGTTGGATGCCTATGTCGCAGTATCTGTC
Extension primer: TGATTCCTGCCTCATCC
263 A-G Forward primer: ACGTTGGATGTTAAGTGCTGTGGCCAGAAG
Reverse primer: ACGTTGGATGATAACAATTGAATGTCTGC
Extension primer: TGAATGTCTGCACAGCC
3 16069 C-T Forward primer: ACGTTGGATGGTGGCTGGCAGTAATGTACG
Reverse primer: ACGTTGGATGGAAGCAGATTTGGGTACCAC
Extension primer: CCACCCAAGTATTGACT
16324 T-C Forward primer: ACGTTGGATGTCATCCATGGGGACGAGAAG
Reverse primer: ACGTTGGATGAACCTACCCACCCTTAACAG
Extension primer: ATTTACCGTACATAGCACAT
16366 C-T Forward primer: ACGTTGGATGGCGGGATATTGATTTCACGG
Reverse primer: ACGTTGGATGGCACATTACAGTCAAATCCC
Extension primer: AAATCCCTTCTCGTCCC
16390 G-A Forward primer: ACGTTGGATGAGTCAAATCCCTTCTCGTCC
Reverse primer: ACGTTGGATGGCGGGATATTGATTTCACGG
Extension primer: GATGGTGGTCAAGGGAC
73 A-G Forward primer: ACGTTGGATGTATTAACCACTCACGGGAGC
Reverse primer: ACGTTGGATGAGCGTCTCGCAATGCTATCG
Extension primer: TCGCAATGCTATCGCGTGCA
185 G-A Forward primer: ACGTTGGATGGTGCAGACATTCAATTGTTA
Reverse primer: ACGTTGGATGTATCGCACCTACGTTCAATA
Extension primer: CACCTACGTTCAATATTACAG
188 A-G Forward primer: ACGTTGGATGCGCACCTACGTTCAATATTA
Reverse primer: ACGTTGGATGGCTGTGCAGACATTCAATTGT
Extension primer: TTAACACACTTTAGTAAGTATGT
228 G-A Forward primer: ACGTTGGATGAAGTGGCTGTGCAGACATTC
Reverse primer: ACGTTGGATGGGCGAACATACTTACTAAAG
Extension primer: TGTGTTAATTAATTAATGCTTGTAG
263 A-G Forward primer: ACGTTGGATGTTAAGTGCTGTGGCCAGAAG
Reverse primer: ACGTTGGATGATAACAATTGAATGTCTGC
Extension primer: TGAATGTCTGCACAGCC
295 C-T Forward primer: ACGTTGGATGTTAAGTGCTGTGGCCAGAAG
Reverse primer: ACGTTGGATGCCACTTTCCACACAGACATC
Extension primer: ACAGACATCATAACAAAAAATTT
315 C-CC Forward primer: ACGTTGGATGGCTGGTGTTAGGGTTCTTTG
Reverse primer: ACGTTGGATGAAATTTCCACCAAACCCCCC
Extension primer: CAAACCCCCCCTCCCCC
462 C-T Forward primer: ACGTTGGATGTGTGTGTGCTGGGTAGGATG
Reverse primer: ACGTTGGATGTTTAACAGTCACCCCCCAAC
Extension primer: AACACATTATTTTCCCCTC
489 T-C Forward primer: ACGTTGGATGTTAGCAGCGGTGTGTGTGTG
Reverse primer: ACGTTGGATGTTATTTTCCCCTCCCACTCC
Extension primer: CCCATACTACTAATCTCATCAA
522 C-del Forward primer: ACGTTGGATGTCTCATCAATACAACCCCCG
Reverse primer: ACGTTGGATGTTTGGTTGGTTCGGGGTATG
Extension primer: TATGGGGTTAGCAGCGGT
523 A-del Forward primer: ACGTTGGATGTTTGGTTGGTTCGGGGTATG
Reverse primer: ACGTTGGATGTCTCATCAATACAACCCCCG
Extension primer: CTACCCAGCACACACAC
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Table 2 Quantities of mtDNA and nDNA in the samples of
platelet-apheresis products.
Case mtDNA quantities, GAPDH, Ratio
GE/mL GE/mL mtDNA/nDNA
1 2,911,332 1073 2713
2 869,667 1123 774
3 3,492,084 4039 865
No positive amplifications were obtained from the cell
line using the 18 primer pairs listed in Table 1.
Sensitivity of MALDI-TOF MS for detecting mtDNA
polymorphisms
To determine the sensitivity of MALDI-TOF MS for
analyzing mtDNA SNPs, we designed experiments by
diluting known amounts of mtDNA five-fold with
informative polymorphisms in a series from
5=104 GE to 5 GE (1 GE/mL) per PCR reaction. Anal-
ysis for informative polymorphisms was performed
using MALDI-TOF MS. The assay enabled the reliable
identification of the polymorphisms using as little as
5 GE per PCR reactions. In our other study, where we
used MALDI-TOF MS to identify point mutations on
single cell level, close to 70% of the successful anal-
ysis was achieved (data not shown).
A dilution series (2.5=104, 5=104, 10=104, 25=104,
50=104 GE) of mtDNA with an informative polymor-
phism was mixed with mtDNA molecules (1=106 GE)
not carrying the same polymorphism, to give a ratio
ranging from 2.5%, 5%, 10%, 25% and to 50% of
mtDNA molecules with the polymorphism to those
without the polymorphism. MALDI-TOF MS could dis-
criminate down to the level of 5% of polymorphism-
containing mtDNA in a 95% background of mtDNA
lacking the polymorphism (Figure 1). We compared
the sensitivity using MALDI-TOF with those using
sequencing analysis (Figure 2).
Detection of mtDNA polymorphisms in three
individuals using uniplex and multiplex assays
From three individuals, 18 mtDNA polymorphisms
were identified by sequencing analysis. The positions
and nature of the polymorphisms in the three individ-
uals are listed in Table 1.
A total of 18 uniplex assays for each polymorphism
and 3–12 multiplexed assays using MALDI-TOF MS
were developed. The results were compared with
those obtained by sequencing analysis. No false pos-
itive and false negative results were obtained using
the MALDI-TOF MS assays. The uniplex assays and
the multiplex assays showed good concordance
regarding the determination of the polymorphisms.
Discussion
Rapid and accurate identification of physiologic and
pathogenic mtDNA variants is an important issue in
life science. In this study, we evaluated the sensitivity
and specificity of MALDI-TOF MS for the detection of
SNPs mtDNA on hypervariable regions.
To evaluate the specificity of MALDI-TOF MS for
detection of mtDNA SNPs, the assays for 18 mtDNA
SNPs in this study were tested by using a mitochon-
dria negative cell line. No mtDNA was detectable
from the cell line by both MALDI-TOF MS and
sequencing. In our study, we co-extracted mtDNA
with nDNA using commercial kits. The contaminated
co-extraction of nDNA did not alter our results regard-
ing the detection of mtDNA SNPs.
The detection limit achieved with the assay corre-
sponded to the identification of 5 GE of mtDNA per
reaction after first round PCR amplification. As a
human eukaryotic cell contains hundreds or
thousands of mtDNA (16), the sensitive MALDI-TOF
MS established in our study could enable the analysis
of mtDNA SNPs from less than one cell.
In our study, MALDI-TOF MS enabled the discrimi-
nation of as little as 5% of the mtDNA polymorphism
in the predominating background of mtDNA not con-
taining the SNP. Several studies using MALDI-TOF
MS for genetic analysis support our results regarding
the sensitivity of this assay for mtDNA detection. In
our group, Li et al. could detect very rare fetal genetic
materials in maternal blood (12). The concentration of
fetal DNA in maternal circulation is considerably low,
comprising 3.7% of total DNA as quantified by real-
time quantitative analysis (17). A previous study from
our laboratory also showed that donor-derived genet-
ic materials could be sensitively detected in the urine
of kidney transplant recipients using MALDI-TOF MS
(13).
In our group, Li et al. compared the MALDI-TOF MS
assay with a well-established TaqMan real-time PCR
assay for the detection of rare fetal genetic material
in the maternal circulation. The MALDI-TOF MS assay
and the TaqMan real-time PCR assay had similar
detection rates in terms of non-invasive prenatal iden-
tification of fetal gender (18). However, identification
of multiple SNPs by individual allele-specific TaqMan
real-time PCR is a time-consuming and laborious
process. Furthermore, SNPs, which only differ mini-
mally from the wild-type DNA of interest, make the
design of allele-specific PCR especially challenging
(19).
The iPLEX Assay developed by Sequenom,
Inc. enables up to 36–40 multiplex PCR and primer
extension reactions per assay, so that 36–40 muta-
tions can be detected simultaneously in a single reac-
tion. The multiplexed genotyping assays rely on the
natural molecular weight differences of DNA bases.
In our study, we analyzed the 18 SNPs using uniplex
and multiplex assays in parallel. The precision and
accuracy of the mass determination by multiplex i-
PLEX assay at 3–12 levels were comparable with
those by uniplex assay. There were no false positive
or false negative signals from the MALDI-TOF MS
method, as compared to the results obtained by
sequencing. The method demonstrated a high con-
cordance of results and 100% accuracy when com-
pared with capillary sequencing, suggesting that
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Figure 1 MALDI-TOF MS discriminates rare SNP-containing mtDNA in the background of mtDNA lacking the polymorphism.
mtDNA sample containing the SNP of an ‘‘A-deletion’’ at the position of 523 was mixed into the mtDNA sample without an
‘‘A-deletion’’ at the same position. Panels (A) and (B) show the reproducible detections of as little as 5% of the ‘‘A-deletion’’-
containing mtDNA in the 95% background molecules by MALDI-TOF MS. Panel (C) shows a mini-peak on MALDI-TOF MS for
the detection of as little as 2.5% of the ‘‘A-deletion’’-containing mtDNA in the 97.5% background molecules.
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Figure 2 Comparison of MALDI-TOF and sequencing analysis for the sensitivity test.
mtDNA sample containing the SNP of ‘‘T’’ at the position of 462 was mixed into the mtDNA sample containing a ‘‘C’’ at the
same position. Panel (A) shows the results by MALDI-TOF MS and sequencing analysis for the mixture of 50%–50%. Panel
(B) shows the results by MALDI-TOF MS and sequencing analysis for the mixture of 5%–95%.
mass spectrometric analysis of SNPs is a robust and
reproducible technique for the detection of mtDNA
mutations. Multiplex assays enable the rapid detec-
tion of polymorphisms and reduce the amount of
DNA input required and the costs for multiple geno-
typing. The possibility of analyzing up to 384 samples
on a single chip enables high-throughput detections
in large-scale studies.
Possible fields which could benefit from this power-
ful and sensitive tool include forensic medicine and
transplantation immunology, particularly when the
target mtDNA input is limited (20). This approach can
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also be used for the tracing of matrilineage with large-
scale multiple genotyping. Further potential applica-
tions may be possible in the field of transfusion
medicine, in the diagnosis of mtDNA mutation related
disorders, and in research regarding aging, apoptosis
and carcinogenesis based on physiologic and patho-
genic alterations of mtDNA.
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